Patamostat mesylate

Drug Profile

Patamostat mesylate

Alternative Names: E 3123

Latest Information Update: 17 Jan 2001

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Benzoic acids; Small molecules
  • Mechanism of Action Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pancreatitis

Most Recent Events

  • 17 Jan 2001 No-Development-Reported for Pancreatitis in Japan (IV)
  • 10 Nov 1995 Four preclinical studies have been added to the pharmacodynamics section ,,,.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top